AfterRaise/Companies/FORE Biotherapeutics

FORE Biotherapeutics

FORE Biotherapeutics is a registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients with cancer. From its funding announcement.

$67M Series DRaised 3 months agoPhiladelphia, USABiotech & PharmaUSA
Visit website →

In their own words

What FORE Biotherapeutics says it is doing

Work here? Claim your company profile

Public signal Described in the funding announcement as "registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients with cancer". Source

Regulatory

Public signal Read from the company's own description of what the funding supports.

Why now

Where FORE Biotherapeutics is today

FORE Biotherapeutics announced a Series D round of $67M on 8 July 2026, led by SR One.

Latest round
Series D
Amount
$67M
Announced
8 July 2026
Headquarters
Philadelphia, USA
Sector
Biotech & Pharma
Growth stage
Series C+
Investors
Also participating
TaiAx, LG Technology Ventures, Primer Ventures, Axil, all, OrbiMed Advisors, HBM Healthcare Investments, Wellington Management, Cormorant Capital, Novartis Venture Fund, Windham Life Science Partners, Samsung, 3B Capital
Relevant leadership
CEO William Hinshaw

Momentum AfterRaise intelligence

AfterRaise Score

57
Steady growth
0 funding signals in the last 90 days
Funding recency
18/40
announced within the last 6 months
Round scale
19/25
round size relative to the market
Funding stage
20/20
Series D
Funding cadence
0/15
one funding event tracked this year
Arriving with the signals layer
  • Hiring momentum Open roles and hiring pace
  • Market expansion New offices and new countries
  • Leadership Executive appointments
  • Product activity Launches and releases

Since the raise

What has happened since

  • 8 July 2026
    $67M Series D
    Led by SR One.

Public signal The timeline currently holds funding events, because those are the signals AfterRaise observes today. Hiring, leadership, expansion and product events join it with the signals layer.

What may happen next

What this raise could create

AfterRaise intelligenceNot a statement of fact

What may happen next

  • Regulatory and certification milestones
  • Compliance team growth
  • Accelerated hiring across functions
  • Multi-market operations

Opportunities this could create

  • Regulatory affairs
  • Quality systems
  • Scientific hiring
  • Regulatory advisers
  • Certification specialists

Based on the Biotech & Pharma sector, a Series C+ round and the priorities the company itself set out. Not a statement of fact.

Medium momentum2 connected signals
  • 8 July 2026$67M Series D announced
  • 8 July 2026Stated priority: regulatory

High momentum means several meaningful company changes have occurred in a short period. Signals here are funding events and the priorities the company stated; hiring, leadership and expansion detection join with the signals layer.

Open to

What FORE Biotherapeutics is open to

Not yet specified

FORE Biotherapeutics has not told AfterRaise which approaches it welcomes. Until it does, we do not assume. Offers to help are held and shown to the company, and the company decides whether to open a conversation.

Work here? Set your preferences

Opportunities

Ways to work with FORE Biotherapeutics

No open opportunities listed

Jobs, projects, partnerships, advisory and supplier needs appear here once the company has claimed its page and published them, and any role we read from its own job board appears automatically.

Work here? Open the first one

Helpful contributors

People who have contributed here

Nobody yet

When someone offers help and the company says it was useful, they appear here. Reputation on AfterRaise is built from contributions the company confirmed, not from follower counts.

Do you work at FORE Biotherapeutics?

Claim your company profile.

This page was created from publicly available information. A verified representative corrects the record, says what the company is building next and chooses which conversations it welcomes.

What we do not have yet: the roles and projects you have open. Claiming the page is how you fill those in.

Someone else requesting access does not give them ownership. Every representative is verified by a person before access is granted.

Maintaining your own company profile is free. A founder, CEO or authorised senior colleague can represent the company.

Also moving

Other Biotech & Pharma companies

See the sector